Johnson & Johnson (JNJ) To Go Ex-Dividend on November 24th

Johnson & Johnson (NYSE:JNJ – Get Free Report) announced a quarterly dividend on Tuesday, October 13th. Shareholders of record on Tuesday, November 24th will be given a dividend of $1.34 per share on Tuesday, December 8th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.1%. The ex-dividend date is Tuesday, November 24th.

Johnson & Johnson has raised its dividend by an average of 0.1% annually over the last three years and has raised its dividend every year for the last 64 years. Johnson & Johnson has a dividend payout ratio of 48.3% meaning its dividend is sufficiently covered by earnings. Analysts expect Johnson & Johnson to earn $12.13 per share next year, which means the company should continue to be able to cover its $5.36 annual dividend with an expected future payout ratio of 44.2%.

Get Johnson & Johnson alerts:

Johnson & Johnson Stock Up 2.0%

Johnson & Johnson stock opened at $253.49 on Thursday. Johnson & Johnson has a 12 month low of $184.66 and a 12 month high of $281.07. The stock has a fifty day simple moving average of $265.80 and a two-hundred day simple moving average of $249.47. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44. The firm has a market cap of $610.89 billion, a price-to-earnings ratio of 38.41, a PEG ratio of 2.54 and a beta of 0.21.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.53 by $0.06. Johnson & Johnson had a return on equity of 31.54% and a net margin of 16.20%. The firm had revenue of $25.40 billion for the quarter, compared to the consensus estimate of $25.38 billion. During the same period in the prior year, the company posted $2.80 earnings per share. The company’s quarterly revenue was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Equities analysts predict that Johnson & Johnson will post 11.10 EPS for the current fiscal year.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson reported adjusted third-quarter EPS of $2.59, above the $2.53 consensus estimate, while revenue increased 5.9% year over year to approximately $25.4 billion. Innovative Medicine was the main growth driver, with pharmaceutical sales benefiting from oncology products, TREMFYA and newer medicines. Johnson & Johnson Q3 Earnings Surpass Estimates
• Positive Sentiment: Management raised its full-year 2026 outlook to $101.0 billion-$101.4 billion in revenue and adjusted EPS of $11.05-$11.15. The company also declared a quarterly dividend of $1.34 per share, supporting JNJ’s income-investment appeal. Johnson & Johnson raises 2026 guidance as quarterly sales climb
• Positive Sentiment: Royal Bank of Canada maintained an “outperform” rating, although it lowered its price target from $290 to $280. Management is also considering a mid-2027 spinoff of its DePuy Synthes orthopedics business, which could sharpen the focus of the remaining MedTech operations. Johnson & Johnson MedTech sets mid-2027 target for ortho spinoff
• Neutral Sentiment: Analysts expect JNJ’s December 8 enterprise review to provide more detail on portfolio strategy, MedTech investments and the potential orthopedics separation. The review could clarify the company’s longer-term growth plan. Johnson & Johnson’s Enterprise Review Expected to Sharpen Outlook
• Negative Sentiment: MedTech sales missed Wall Street expectations, with weakness in cardiovascular and surgery businesses, particularly outside the United States. China pricing pressure, European budget reductions and Middle East-related disruptions added to concerns about the segment’s near-term growth.
• Negative Sentiment: Reported profit was sharply reduced by special charges tied to the proposed talc litigation resolution, the Firefly Bio acquisition and the Sail Biomedicines collaboration. Analysts subsequently trimmed several earnings estimates and price targets, while management warned that new drug deals could dilute 2027 earnings. Johnson & Johnson falls after quarterly report despite higher 2026 outlook

About Johnson & Johnson

(Get Free Report)

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.

See Also

• Five stocks we like better than Johnson & Johnson
• Tesla Wants to Make Its Own Chips—What Could Go Wrong?
• IREN Limited’s AI Pivot Gains Traction—But Can Its Data Centers Deliver?
• PBF Energy’s Stunning Rally Faces a Critical Test
• Citi Stock Falls Despite Earnings Beat: What Investors Need to Know

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.